Skip to main content
Top
Published in: Metabolic Brain Disease 2/2019

01-04-2019 | Multiple Sclerosis | Short Communication

Evaluation strategy to determine reliable demyelination in the cuprizone model

Authors: Uta Chrzanowski, Christoph Schmitz, Anja Horn-Bochtler, Anne Nack, Markus Kipp

Published in: Metabolic Brain Disease | Issue 2/2019

Login to get access

Abstract

In multiple sclerosis patients, chronic clinical deficits are known to result from axonal degeneration which is triggered by inadequate remyelination. The underlying molecular mechanisms of remyelination and its failure remain currently unclear. In vivo models, among the cuprizone model, are valuable tools to study underlying mechanisms of remyelination and its failure. Since complete and reproducible demyelination of the analyzed brain region is an indispensable prerequisite for efficient remyelination experiments, in this study we systematically addressed which part of the corpus callosum is reliably and consistently demyelinated after acute cuprizone-induced demyelination. Following a novel evaluation strategy, we can show that at the level of the rostral hippocampus, the most medial sectors of the corpus callosum (spanning 500 μm in the horizontal plane) are consistently demyelinated, whereas more lateral sectors show inconsistent and incomplete demyelination. These results precisely define a part of the corpus callosum which should be used as a region of interest during remyelination experiments.
Literature
go back to reference Lucchinetti C, Bruck W, Parisi J, Scheithauer B, Rodriguez M, Lassmann H (2000) Heterogeneity of multiple sclerosis lesions: implications for the pathogenesis of demyelination. Ann Neurol 47:707–717CrossRefPubMed Lucchinetti C, Bruck W, Parisi J, Scheithauer B, Rodriguez M, Lassmann H (2000) Heterogeneity of multiple sclerosis lesions: implications for the pathogenesis of demyelination. Ann Neurol 47:707–717CrossRefPubMed
go back to reference Stidworthy MF, Genoud S, Suter U, Mantei N, Franklin RJ (2003) Quantifying the early stages of remyelination following cuprizone-induced demyelination. Brain Pathol (Zurich, Switzerland) 13:329–339CrossRef Stidworthy MF, Genoud S, Suter U, Mantei N, Franklin RJ (2003) Quantifying the early stages of remyelination following cuprizone-induced demyelination. Brain Pathol (Zurich, Switzerland) 13:329–339CrossRef
Metadata
Title
Evaluation strategy to determine reliable demyelination in the cuprizone model
Authors
Uta Chrzanowski
Christoph Schmitz
Anja Horn-Bochtler
Anne Nack
Markus Kipp
Publication date
01-04-2019
Publisher
Springer US
Published in
Metabolic Brain Disease / Issue 2/2019
Print ISSN: 0885-7490
Electronic ISSN: 1573-7365
DOI
https://doi.org/10.1007/s11011-018-0375-3

Other articles of this Issue 2/2019

Metabolic Brain Disease 2/2019 Go to the issue